98%
921
2 minutes
20
Unlabelled: Bioengineering of viruses and virus-like particles (VLPs) is a well-established approach in the development of new and improved vaccines against viral and bacterial pathogens. We report here that the capsid of a major avian pathogen, infectious bursal disease virus (IBDV), can accommodate heterologous proteins to induce protective immunity. The structural units of the ~70-nm-diameter T=13 IBDV capsid are trimers of VP2, which is made as a precursor (pVP2). The pVP2 C-terminal domain has an amphipathic α helix that controls VP2 polymorphism. In the absence of the VP3 scaffolding protein, 466-residue pVP2 intermediates bearing this α helix assemble into genuine VLPs only when expressed with an N-terminal His6 tag (the HT-VP2-466 protein). HT-VP2-466 capsids are optimal for protein insertion, as they are large enough (cargo space, ~78,000 nm(3)) and are assembled from a single protein. We explored HT-VP2-466-based chimeric capsids initially using enhanced green fluorescent protein (EGFP). The VLP assembly yield was efficient when we coexpressed EGFP-HT-VP2-466 and HT-VP2-466 from two recombinant baculoviruses. The native EGFP structure (~240 copies/virion) was successfully inserted in a functional form, as VLPs were fluorescent, and three-dimensional cryo-electron microscopy showed that the EGFP molecules incorporated at the inner capsid surface. Immunization of mice with purified EGFP-VLPs elicited anti-EGFP antibodies. We also inserted hemagglutinin (HA) and matrix (M2) protein epitopes derived from the mouse-adapted A/PR/8/34 influenza virus and engineered several HA- and M2-derived chimeric capsids. Mice immunized with VLPs containing the HA stalk, an M2 fragment, or both antigens developed full protection against viral challenge.
Importance: Virus-like particles (VLPs) are multimeric protein cages that mimic the infectious virus capsid and are potential candidates as nonliving vaccines that induce long-lasting protection. Chimeric VLPs can display or include foreign antigens, which could be a conserved epitope to elicit broadly neutralizing antibodies or several variable epitopes effective against a large number of viral strains. We report the biochemical, structural, and immunological characterization of chimeric VLPs derived from infectious bursal disease virus (IBDV), an important poultry pathogen. To test the potential of IBDV VLPs as a vaccine vehicle, we used the enhanced green fluorescent protein and two fragments derived from the hemagglutinin and the M2 matrix protein of the human murine-adapted influenza virus. The IBDV capsid protein fused to influenza virus peptides formed assemblies able to protect mice against viral challenge. Our studies establish the basis for a new generation of multivalent IBDV-based vaccines.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325719 | PMC |
http://dx.doi.org/10.1128/JVI.03025-14 | DOI Listing |
Ann Geriatr Med Res
September 2025
Academia Latinoamericana de Medicina del Adulto Mayor - ALMA.
Background: Respiratory infections significantly impact older adults in Latin America, highlighting the need for regionally adapted consensus-based vaccination recommendations to guide preventive strategies. This study aimed to develop a consensus among Latin American experts on vaccination against respiratory diseases in older adults in the region, including influenza, Streptococcus pneumoniae pneumonia, COVID-19, respiratory syncytial virus (RSV), and pertussis.
Methods: A two-round Delphi methodology was employed, involving 35 specialists from various medical fields.
Influenza Other Respir Viruses
September 2025
Department of Respiratory, Children's Hospital of Nanjing Medical University, Nanjing, China.
Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory diseases in children, especially in infants. The immune responses induced by RSV infection are a fairly complex process that can contribute significantly to disease severity. Despite decades of research on RSV, many immune mechanisms remain to be explored.
View Article and Find Full Text PDFVirology
August 2025
ICMR-National Institute of Virology, 130/1, Sus Road, Pashan, Pune, 411021, India; ICMR-National Institute of Virology, 20/A, Dr. Ambedkar Road, Pune, 411001, India.
Highly pathogenic avian influenza (HPAI) clade 2.3.4.
View Article and Find Full Text PDFInfluenza Other Respir Viruses
September 2025
Public Health Agency, Belfast, UK.
Background: We evaluated the effectiveness of the influenza vaccine programme against infection among emergency hospital admissions with respiratory conditions in Northern Ireland during the 2023/2024 influenza season.
Methods: Using a test-negative design, we compared the odds of vaccination between patients who tested positive (cases) and negative (controls) for laboratory-confirmed influenza, adjusting for confounders. VE was stratified by age group, sex and time since vaccination.
J Infect Chemother
September 2025
Department of Pediatrics, Saku Central Hospital Advanced Care Center, Nagano, Japan.
Background: Influenza remains a major public health issue, leading to millions of severe cases and many deaths annually. Although educational and childcare institutions are key transmission points for the spread of the virus in communities, few studies have comprehensively examined the vaccination rates and their determinants in these settings.
Methods: We conducted a nationwide web-based survey to assess influenza knowledge, perceptions, and determinants of vaccine hesitancy based on the 5C model among childcare and educational professionals in Japan.